Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -28.46% is 42% above its 2-year average of -49.08%, near the high end of its 2-year range (-168.86%–-22.62%).
As of the fiscal period ended Tuesday, June 30, 2026. 10.21% below its 12-month average of -25.83%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -28.46%.
RETURN ON EQUITY (ROE)
-28.46%
RETURN ON EQUITY (ROE) AVG TTM
-25.83%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-10.21%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-36.00%
median of 390 covered companies
CURRENT VS SECTOR MEDIAN
+20.94%
vs the sector median at left
Beta Bionics, Inc.
Market Cap
$852.55M
Return on Equity (ROE)
-28.46%
TTM Avg
-25.83%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$844.28M
Return on Equity (ROE)
-97.08%
TTM Avg
-96.94%
3Y Avg
-22.72%
5Y Avg
-22.72%
Market Cap
$867.60M
Return on Equity (ROE)
-33.06%
TTM Avg
-24.59%
3Y Avg
-41.17%
5Y Avg
-18.72%
Market Cap
$837.43M
Return on Equity (ROE)
-37.38%
TTM Avg
-29.74%
3Y Avg
-41.86%
5Y Avg
-72.28%
Market Cap
$819.44M
Return on Equity (ROE)
-13.30%
TTM Avg
11.91%
3Y Avg
154.09%
5Y Avg
54.89%
Market Cap
$903.13M
Return on Equity (ROE)
-24.02%
TTM Avg
-108.12%
3Y Avg
-89.93%
5Y Avg
-68.76%
Market Cap
$915.95M
Return on Equity (ROE)
23.86%
TTM Avg
-5.16%
3Y Avg
-37.28%
5Y Avg
-22.23%
Market Cap
$786.48M
Return on Equity (ROE)
-25.03%
TTM Avg
-10.49%
3Y Avg
-5.87%
5Y Avg
-23.97%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $852.55M | -28.46% | -25.83% | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $844.28M | -97.08% | -96.94% | -22.72% | -22.72% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -33.06% | -24.59% | -41.17% | -18.72% |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -37.38% | -29.74% | -41.86% | -72.28% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | -13.30% | 11.91% | 154.09% | 54.89% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -24.02% | -108.12% | -89.93% | -68.76% |
| Bioventus Inc. (BVS)vs › | $915.95M | 23.86% | -5.16% | -37.28% | -22.23% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -25.03% | -10.49% | -5.87% | -23.97% |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 5.94% | 5.38% | 4.71% | 4.13% |
ROE
-28.5%
ROA
-25.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -28.46% |
| 2026-03-31 | -24.49% |
| 2025-12-31 | -25.45% |
| 2025-09-30 | -26.41% |
| 2025-06-30 | -24.32% |
| 2025-03-31 | -22.62% |
| 2024-12-31 | -72.04% |
| 2024-09-30 | -168.86% |
